Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Lead nephropathy: In vivo x ray fluorescence (XRF) for assessing body lead stores

Conference ·
OSTI ID:6935255

The EDTA lead mobilization test has proven of value in the diagnosis of renal disease due to lead (lead nephropathy) but is unsuitable for large scale studies in patients with end-stage renal disease. A rapid, safe, non-invasive technique for determining body lead stores by in vivo tibial x ray fluorescence (XRF) is described. These studies show that the chelation test can be replaced by in vivo XRF in patients with end-stage renal disease. XRF, for the first time, will permit epidemiologic studies of large populations which may be at risk for lead nephropathy from excessive exposure to environmental lead. 15 refs., 2 figs.

Research Organization:
Brookhaven National Lab., Upton, NY (USA); Veterans Administration Medical Center, East Orange, NJ (USA); University of Medicine and Dentistry of New Jersey, Newark (USA)
DOE Contract Number:
AC02-76CH00016
OSTI ID:
6935255
Report Number(s):
BNL-38902; CONF-8609203-2; ON: DE87003200
Country of Publication:
United States
Language:
English